On this page

Direct-to-patient pharma attribution connects a drugmaker's ad spend to what happens after a patient leaves the brand site: the telehealth visit, the consult, the prescription, the paid fill and the refills. Those steps happen in partner systems the drugmaker doesn't run, and cash-pay fills often miss claims data: patients in direct-to-consumer programs “can disappear from closed payer claims data even though treatment has not stopped” (HealthVerity, January 14, 2026). With Curve Compliance, the method is to measure at the partner. Each telehealth or pharmacy partner sends a stripped-down event at each step, carrying the campaign that brought the patient and no name or contact details, and the drugmaker receives aggregate results by channel, campaign and partner, including cost per paid fill.

Book a call. Planning how a direct-to-patient program will be measured? Curve's team can walk your brand, analytics and privacy teams through the events each partner would send and the aggregate reports you would receive. Book a call with Curve.

What is direct-to-patient pharma attribution?

Drugmakers now sell some medicines straight to patients who pay cash, through manufacturer platforms. L.E.K. Consulting writes that “Biopharma leaders are increasingly treating DTC as a durable commercialization component rather than a tactical add-on,” and its Figure 1 lists 11 manufacturer platforms, among them LillyDirect, NovoCare and PfizerForAll (L.E.K. Consulting, 2026). On its fourth-quarter 2025 earnings call, Eli Lilly said: “The number of people engaging with our US direct-to-patient platform reached 1 million patients in 2025” (Eli Lilly earnings call, February 4, 2026).

A patient in one of these programs usually sees an ad, lands on a brand or program site, starts a telehealth visit with a partner, receives a prescription if the clinician decides it is appropriate, and pays for the fill at a partner pharmacy. Refills follow if the patient stays on therapy. Attribution is the work of tying each of those steps back to the channel and campaign that started the journey, so the brand team can see which spend produces paid fills rather than clicks.

The industry is still settling how to measure this. The Digital Medicine Society launched an initiative with leading pharma organizations and other founding partners that “will also define how to measure patient access and affordability” (Digital Medicine Society, April 16, 2026). DiMe's CEO wrote that the direct-to-patient pathway is expanding “far faster than the oversight, standards, and evidence needed to keep pace” (pharmaphorum, December 2, 2025).

Why can't claims data or ad platform reports see a paid fill?

Claims data sees a prescription when insurance adjudicates it. HealthVerity explains that “When prescriptions are paid for out of pocket, they often fall outside standard pharmacy benefit workflows,” and that “As patients shift to cash-pay options, pharmacy claims may no longer be generated” (HealthVerity, January 14, 2026). IQVIA lists “Poor insight into patient access routes, including out-of-pocket purchasing, online pharmacies” among the limits of the data sources most teams use for obesity (IQVIA, 2026). A cash-pay program measured only through those sources can undercount its own patients.

Ad platform reports have the opposite blind spot. A browser pixel or a server-side event sees what happens on the brand site, such as a page view or a sign-up. The consult, the prescription and the paid fill happen later, inside the telehealth partner's and the pharmacy's own systems. A platform's cost per conversion therefore stops at the last step the brand site itself can observe, which is usually several steps short of a paid fill.

That leaves the partners as the one place where every later step is recorded. Measuring there, rather than in claims, is what makes cost per paid fill possible for a cash-pay program. It also means the measurement design has to work for the partners: few fields, no patient identities, and a connection they set up once.

What gets measured at each step, and who records it?

In this method, each step has one owner, and each event carries the step, the time and the campaign reference, with no name or contact details.

StepRecorded byWhat the event carries
Ad click and site visitThe brand or program site, through one Curve script that replaces browser ad pixelsThe channel and campaign that brought the visitor
Telehealth visit startedThe telehealth partner's intakeThe campaign reference, kept attached when the visitor leaves the brand site
Consult completedThe telehealth partnerStep, time and campaign reference, with no name or contact details
PrescriptionThe telehealth partnerStep, time and campaign reference, with no name or contact details
Paid fillThe pharmacy partnerStep, time and campaign reference, with no name or contact details
Refills at month 3 and month 6The pharmacy partnerCounted by partner and reported in aggregate

Curve keeps the ad click attached when a visitor leaves your site for a booking or intake step on another system. That is built in for common booking tools, other systems are connected through setup by Curve's team, and outcomes recorded days later still match. A partner can send each later step through an incoming webhook or a file upload from its CRM or EHR, and Curve credits each one to the original ad click.

The definitions matter as much as the plumbing. Agree with every partner what counts as a completed consult, when a prescription counts as filled, and how transfers and restarts are handled. If one partner reports a fill at payment and another at shipment, their numbers will not line up, however clean the data is.

What does the drugmaker receive?

In this method, the drugmaker receives aggregate results by channel, campaign and partner: how many visits, consults, prescriptions and paid fills each campaign produced, and the cost per paid fill. Campaign Reporting puts Meta and Google Ads spend next to Curve-tracked conversions per platform and campaign, with five attribution models, so cost per paid fill can be read by campaign for that spend. Retention can be reported the same way: refills at month 3 and month 6, by partner, in aggregate.

Those reports answer the questions a brand, media or analytics team brings to a direct-to-patient program:

  • Which campaigns bring patients who reach a paid fill? Clicks and sign-ups can look alike across campaigns while paid fills differ widely.
  • Where do patients drop off? Between visit and consult, consult and prescription, or prescription and paid fill, read by channel and by partner.
  • How does each partner convert visits into paid fills? The same campaign can perform differently at different partners, and the partner view shows where.
  • Do patients stay on therapy? Refills at month 3 and month 6 show whether a partner's patients continue, not just whether they start.

For the metric most brand teams start with, cost per patient start, define a start as a new patient's first paid fill and keep that definition the same at every partner.

How do telehealth and pharmacy partners connect?

Each partner connects once and sees its own results, and the partner tools are open to every partner in the program. A partner can send step events through an incoming webhook, or upload them as a file from its CRM or EHR. The events carry the step, the time and the campaign reference, with no name or contact details.

Curve's team does the setup, typically live in about a week, case by case. A program with several telehealth and pharmacy partners connects each one in turn, with the same event names and definitions. Partner agreements decide what each partner may share and with whom, so talk to your counsel about them before the program starts.

How is patient privacy protected along the way?

Two flows run side by side. The first is the brand site. Curve replaces browser ad pixels with one script and sends conversions server-side from Curve's servers to Meta Conversions API, Google Ads, TikTok, Microsoft Advertising and LinkedIn. Each platform receives only a fixed list of fields; contact identifiers are off by default and SHA-256 hashed when enabled, and events can use neutral names. Curve strips PHI before data reaches an ad platform and flags PHI-like patterns so they can be stopped at the source. Event Logs show what Curve sent to each platform and what the platform accepted.

The second flow is the partner step events described above. They feed the drugmaker's aggregate reports by channel, campaign and partner, and they carry no name or contact details. For why server-side delivery is only part of the answer on the first flow, see why server-side tracking is not HIPAA compliant by itself.

Whoever runs your measurement, these are practices worth asking for in writing before launch:

  • Minimum group sizes. A number is shown only when enough patients sit behind it, so no small group points to a person.
  • Coarse time windows. Report by week or month rather than by exact time of each event.
  • A contract ban on re-identification. Every recipient of the reports agrees not to try to identify the patients behind them.
  • A record of what left each system. Your privacy team can check what was sent, to whom, and when.

Curve signs a BAA on every plan and holds SOC 2 Type II; see Curve's security page for the details your privacy and legal reviewers will ask about.

How Curve Compliance helps

Curve Compliance gives a direct-to-patient program one measurement path from ad to paid fill. On the brand site, one script replaces browser ad pixels, and site conversions go server-side to the ad platforms with a fixed list of fields. The ad click stays attached when a visitor moves to a partner's intake step. Separately, partners can send consult, prescription and paid fill events through an incoming webhook or a file upload, with no name or contact details, and each event is credited to the original ad click. Those partner-reported steps feed the drugmaker's aggregate reports, where Campaign Reporting puts Meta and Google Ads spend next to them by campaign.

The drugmaker receives aggregate results by channel, campaign and partner, including cost per paid fill and retention at month 3 and month 6. Partners connect once and see their own results, and the partner tools are open to every partner in the program. Curve signs a BAA on every plan, holds SOC 2 Type II, and its team does the setup, typically live in about a week, case by case. See conversion tracking and Curve for pharma and medical devices, or book a call to map your program's steps and partners.

Why claims miss these fills: why cash-pay patients disappear from claims data.

Step by step: how to measure a direct-to-patient program.

Partner view: telehealth partner metrics in a direct-to-patient program.

Privacy: what a direct-to-patient program can send to ad platforms.

Landscape: pharma direct-to-patient programs, explained.

Sources, checked November 20, 2026: HealthVerity, January 14, 2026; IQVIA, Why Obesity Requires a New Evidence Paradigm, 2026; L.E.K. Consulting, The Emergence of Direct-to-Consumer Pharmaceutical Platforms, 2026; Eli Lilly Q4 2025 earnings call, February 4, 2026 (transcript); Digital Medicine Society release, April 16, 2026; pharmaphorum, December 2, 2025.

Frequently Asked Questions

What is direct-to-patient pharma attribution?

It is the work of tying a drugmaker's ad spend to the steps a patient takes after the brand site, from the telehealth visit to the paid fill and refills, by channel, campaign and partner. Because those steps happen in partner systems and cash-pay fills often miss claims data, the events are measured at the telehealth and pharmacy partners.

What does the drugmaker receive?

Aggregate results by channel, campaign and partner: visits, consults, prescriptions, paid fills, cost per paid fill and retention at month 3 and month 6. In this method, partner events carry the step, the time and the campaign reference, with no name or contact details.

Why not measure direct-to-patient programs with claims data?

Cash-pay fills often fall outside insurance workflows, so claims data can miss them; HealthVerity notes such patients “can disappear from closed payer claims data even though treatment has not stopped” (HealthVerity, January 14, 2026). The partners record every step, so they are the place to measure.

Can cost per paid fill be reported by campaign?

Yes, for Meta and Google Ads spend. Campaign Reporting puts that spend next to Curve-tracked conversions per platform and campaign, with five attribution models, so the paid fills partners report can be read as cost per paid fill by campaign.

How do partners send their events?

Through an incoming webhook or a file upload from a CRM or EHR, and Curve credits each event to the original ad click. Each partner connects once and sees its own results.

Can retention be reported by partner?

Yes. Refills at month 3 and month 6 can be reported by partner, in aggregate, which shows whether a partner's patients continue on therapy as well as start.

Does Curve sign a BAA?

Yes. Curve signs a BAA on every plan, holds SOC 2 Type II, and its team does the setup, typically live in about a week, case by case.

Talk to Curve Compliance

Book a call. Want cost per paid fill by channel, campaign and partner for a direct-to-patient program? Curve's team maps the steps and partners with you and does the setup, typically live in about a week, case by case. Book a call with Curve.